Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
Cash from Operating Activities
Clinuvel Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Operating Activities
AU$42.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Cash from Operating Activities
-AU$35.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-10%
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$2.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
AU$23.9m
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Operating Activities
-AU$19.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-22%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
42.3m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Cash from Operating Activities amounts to 42.3m AUD.
What is Clinuvel Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
23%
Over the last year, the Cash from Operating Activities growth was -3%. The average annual Cash from Operating Activities growth rates for Clinuvel Pharmaceuticals Ltd have been 31% over the past three years , 23% over the past five years .